Oncogenic Mutant p53 Gain of Function Nourishes the Vicious Cycle of Tumor Development and Cancer Stem-Cell Formation
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
More than half of human tumors harbor an inactivated p53 tumor-suppressor gene. It is well accepted that mutant p53 shows an oncogenic gain-of-function (GOF) activity that facilitates the transformed phenotype of cancer cells. In addition, a growing body of evidence supports the notion that cancer stem cells comprise a seminal constituent in the initiation and progression of cancer development. Here, we elaborate on the mutant p53 oncogenic GOF leading toward the acquisition of a transformed phenotype, as well as placing mutant p53 as a major component in the establishment of cancer stem cell entity. Therefore, therapy targeted toward cancer stem cells harboring mutant p53 is expected to pave the way to eradicate tumor growth and recurrence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mechanisms of Cancer Drug Resistance
Gottesman, M. M. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.103929 · Cited by 2,643
Hingorani, S. R., Wang, L., Multani, A. S., Combs, C., Deramaudt, T. B., Hruban, R. H., Rustgi, A. K., Chang, S., & Tuveson, D. A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.023 · Cited by 2,609
EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer
Singh, A., & Settleman, J. (2010) · Oncogene · doi:10.1038/onc.2010.215 · Cited by 2,545 · cited 1×
“A set of TFs, including Snail, Slug, Twist1, and Zeb1/2, orchestrates the EMT and related migratory processes during embryogenesis and tumorigenesis (Singh and Settleman 2010).”
BackgroundCancer cell metabolism: warburg and beyond
Hsu, P. P., & Sabatini, D. M. (2008) · Cell · doi:10.1016/j.cell.2008.08.021 · Cited by 2,452
Massive genomic rearrangement acquired in a single catastrophic event during cancer development
Stephens, P. J., Greenman, C. D., Fu, B., Yang, F., Bignell, G. R., Mudie, L. J., Pleasance, E. D., Lau, K. W., Beare, D., Stebbings, L. A., et al. (2011) · Cell · doi:10.1016/j.cell.2010.11.055 · Cited by 2,414
The first 30 years of p53: growing ever more complex.
Levine, A. J., & Oren, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2723 · Cited by 1,967 · cited 2×
“During the past three and a half decades of p53 research, ample data have accumulated pertaining to the role of p53 in the regulation of various cellular processes and in preventing cancer development (Levine and Oren 2009; Bieging et al. 2014).”
BackgroundVariation in cancer risk among tissues can be explained by the number of stem cell divisions
Tomasetti, C., & Vogelstein, B. (2015) · Science · doi:10.1126/science.1260825 · Cited by 1,927
DNA repair pathways as targets for cancer therapy
Helleday, T., Petermann, E., Lundin, C., Hodgson, B., & Sharma, R. A. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2342 · Cited by 1,666 · cited 1×
“This perturbation results in reduced DNA-repair capacity and increased genetic instability in tumor cells (Helleday et al. 2008).”
BackgroundPetitjean, A., Mathe, E., Kato, S., Ishioka, C., Tavtigian, S. V., Hainaut, P., & Olivier, M. (2007) · Human Mutation · doi:10.1002/humu.20495 · Cited by 1,598 · cited 7×
“…(broadly described in Shetzer et al. 2014b), which is one of the reasons for the mut-p53 association with a poor prognosis (Olivier et al. 2005; Petitjean et al. 2007). mut-p53-mediated drug resistance was shown in many tumor types following treatment with different agents (Li et al. 1998;…”
BackgroundInfluentialMutant p53 in Cancer: New Functions and Therapeutic Opportunities
Muller, P. A. J., & Vousden, K. H. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.021 · Cited by 1,545
Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome
Olive, K. P., Tuveson, D. A., Ruhe, Z. C., Yin, B., Willis, N. A., Bronson, R. T., Crowley, D., & Jacks, T. (2004) · Cell · doi:10.1016/j.cell.2004.11.004 · Cited by 1,308 · cited 1×
“Although both mut-p53 and null-p53 mice showed facilitated tumor development, mice harboring mut-p53 displayed significantly higher incidence of metastasis (Lang et al. 2004; Olive et al. 2004).”
BackgroundWhen mutants gain new powers: News from the mutant p53 field
Brosh, R., & Rotter, V. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2693 · Cited by 1,132 · cited 8×
“Importantly, not only does mut-p53 interfere with the remaining WT-p53 protein via dominant negative mechanism, but also mutations empower p53 with oncogenic gain-offunction (GOF) effects that endow cells with tumorigenic potential (Brosh and Rotter 2009; Muller and Vousden 2014).”
BackgroundInfluentialSelf-citationGain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome
Lang, G. A., Iwakuma, T., Suh, Y.-A., Liu, G., Rao, V. A., Parant, J. M., Valentin-Vega, Y. A., Terzian, T., Caldwell, L. C., Strong, L. C., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.006 · Cited by 1,069 · cited 1×
“Although both mut-p53 and null-p53 mice showed facilitated tumor development, mice harboring mut-p53 displayed significantly higher incidence of metastasis (Lang et al. 2004; Olive et al. 2004).”
BackgroundRestoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
Bykov, V. J. N., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K. G., & Selivanova, G. (2002) · Nature Medicine · doi:10.1038/nm0302-282 · Cited by 1,067 · cited 2×
“…first-in-class drugs are able to interact with the DNA-binding domain of multiple p53 mutant proteins, promoting their folding into WT conformation and thereby inducing apoptosis and activating several p53 target genes in human tumor cells carrying mut-p53 (Bykov et al. 2002; Lehmann et al. 2012).”
BackgroundSerine starvation induces stress and p53-dependent metabolic remodelling in cancer cells
Maddocks, O. D. K., Berkers, C. R., Mason, S. M., Zheng, L., Blyth, K., Gottlieb, E., & Vousden, K. H. (2013) · Nature · doi:10.1038/nature11743 · Cited by 1,007 · cited 1×
“As a part of its tumor-suppressive activities, WT-p53 was shown to directly influence various metabolic pathways, enabling cells to respond to metabolic stress (Vousden and Ryan 2009; Maddocks and Vousden 2011; Goldstein and Rotter 2012; Berkers et al. 2013; Maddocks et al. 2013).”
BackgroundVousden, K. H., & Ryan, K. M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2715 · Cited by 959
Rausch, T., Jones, D. T. W., Zapatka, M., Stütz, A. M., Zichner, T., Weischenfeldt, J., Jäger, N., Remke, M., Shih, D., Northcott, P. A., et al. (2012) · Cell · doi:10.1016/j.cell.2011.12.013 · Cited by 865
Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway
Freed-Pastor, W. A., Mizuno, H., Zhao, X., Langerød, A., Moon, S.-H., Rodriguez-Barrueco, R., Barsotti, A., Chicas, A., Li, W., Polotskaia, A., et al. (2012) · Cell · doi:10.1016/j.cell.2011.12.017 · Cited by 865
Weinstein, I. B., & Joe, A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-3293 · Cited by 805 · cited 1×
“Many tumors have shown an apparent dependency on specific gene expression to retain the malignant phenotype (Weinstein and Joe 2008).”
Backgroundp53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation
Zheng, H., Ying, H., Yan, H., Kimmelman, A. C., Hiller, D. J., Chen, A.-J., Perry, S. R., Tonon, G., Chu, G. C., Ding, Z., et al. (2008) · Nature · doi:10.1038/nature07443 · Cited by 767 · cited 2×
“As of today, CSCs with p53 perturbations were successfully isolated by different combination of CSC markers from various cancer types such as gliomas (Zheng et al. 2008; Wang et al. 2009; Friedmann-Morvinski et al. 2012), breast cancer (Vadakkan et al.”
BackgroundNon-Cell-Autonomous Tumor Suppression by p53
Lujambio, A., Akkari, L., Simon, J., Grace, D., Tschaharganeh, D. F., Bolden, J. E., Zhao, Z., Thapar, V., Joyce, J. A., Krizhanovsky, V., et al. (2013) · Cell · doi:10.1016/j.cell.2013.03.020 · Cited by 766 · cited 1×
“Hence, the wild-type p53 (WT-p53) protein is considered the guardian of the genome (Lane 1992) and a key regulator of homeostasis (Vousden and Lane 2007) that exerts its activities both at the cell-autonomous and -nonautonomous levels (Lujambio et al. 2013).”
BackgroundAssessing TP53 status in human tumours to evaluate clinical outcome
Soussi, T., & Béroud, C. (2001) · Nature reviews. Cancer · doi:10.1038/35106009 · Cited by 659
Common markers of proliferation
Whitfield, M. L., George, L. K., Grant, G. D., & Perou, C. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1802 · Cited by 650 · cited 2×
“This set of genes is involved in DNA replication, spindle assembly and checkpoint, chromosome segregation, and mitotic processes (Whitfield et al. 2006).”
BackgroundPRIMA-1 reactivates mutant p53 by covalent binding to the core domain
Lambert, J. M. R., Gorzov, P., Veprintsev, D. B., Söderqvist, M., Segerbäck, D., Bergman, J., Fersht, A. R., Hainaut, P., Wiman, K. G., & Bykov, V. J. N. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.003 · Cited by 592
The expanding universe of p53 targets
Menendez, D., Inga, A., & Resnick, M. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2730 · Cited by 568
p53: traffic cop at the crossroads of DNA repair and recombination
Sengupta, S., & Harris, C. C. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1546 · Cited by 544
Mutant p53 Drives Pancreatic Cancer Metastasis through Cell-Autonomous PDGF Receptor β Signaling
Weissmueller, S., Manchado, E., Saborowski, M., Morris, J. P., Wagenblast, E., Davis, C. A., Moon, S.-H., Pfister, N. T., Tschaharganeh, D. F., Kitzing, T., et al. (2014) · Cell · doi:10.1016/j.cell.2014.01.066 · Cited by 466 · cited 2×
“…down-regulation of Dicer through p63-dependent and -independent means (Muller et al. 2014), inhibition of PDGFRb by blocking the p73/NF-Y complex (Weissmueller et al. 2014), and interactions with NRG1 and Pin1 (Girardini et al. 2011; Coffill et al. 2012). mut-p53 AFFECTS TUMOR STROMA AND…”
BackgroundTumour-associated mutant p53 drives the Warburg effect
Zhang, C., Liu, J., Liang, Y., Wu, R., Zhao, Y., Hong, X., Lin, M., Yu, H., Liu, L., Levine, A. J., et al. (2013) · Nature Communications · doi:10.1038/ncomms3935 · Cited by 434 · cited 2×
“In addition, it was reported that in lung and breast carcinoma, mut-p53 stimulates glucose intake by up-regulating the RhoA-ROCK pathway that results in translocation of GLUT1 to the plasma membrane (Zhang et al. 2013).”
BackgroundDi Agostino, S., Strano, S., Emiliozzi, V., Zerbini, V., Mottolese, M., Sacchi, A., Blandino, G., & Piaggio, G. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.08.013 · Cited by 418 · cited 2×
“The mut-p53/NF-Y protein complex provokes aberrant transactivation of NFY target genes that eventually induces facilitated proliferation (Di Agostino et al. 2006).”
BackgroundLehmann, S., Bykov, V. J. N., Ali, D., Andrén, O., Cherif, H., Tidefelt, U., Uggla, B., Yachnin, J., Juliusson, G., Moshfegh, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.7783 · Cited by 406 · cited 2×
“…first-in-class drugs are able to interact with the DNA-binding domain of multiple p53 mutant proteins, promoting their folding into WT conformation and thereby inducing apoptosis and activating several p53 target genes in human tumor cells carrying mut-p53 (Bykov et al. 2002; Lehmann et al. 2012).”
BackgroundTargeted rescue of a destabilized mutant of p53 by an in silico screened drug
Boeckler, F. M., Joerger, A. C., Jaggi, G., Rutherford, T. J., Veprintsev, D. B., & Fersht, A. R. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805326105 · Cited by 387
Translating p53 into the clinic
Cheok, C. F., Verma, C. S., Baselga, J., & Lane, D. P. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.174 · Cited by 381 · cited 1×
“Notably, PRIMA1MET is the first drug of this class that has reached a clinical phase (Cheok et al. 2011).”
BackgroundLi, D., Marchenko, N. D., & Moll, U. M. (2011) · Cell Death & Differentiation · doi:10.1038/cdd.2011.71 · Cited by 336 · cited 1×
“It was shown that inhibiting HDAC by SAHA disrupts HSP90 and HSP70 protection, which leads to mut-p53 degradation (Li et al. 2011).”
BackgroundThe promises and perils of p53
Krizhanovsky, V., & Lowe, S. W. (2009) · Nature · doi:10.1038/4601085a · Cited by 274
Modulation of the Vitamin D3 Response by Cancer-Associated Mutant p53
Stambolsky, P., Tabach, Y., Fontemaggi, G., Weisz, L., Maor-Aloni, R., Sigfried, Z., Shiff, I., Kogan, I., Shay, M., Kalo, E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.11.025 · Cited by 245 · cited 1×
“Strikingly, we showed that mut-p53 modulates the antiproliferative effects of vitamin D3 by physical interaction with the vitamin D3 receptor, thereby converting vitamin D3 into an antiapoptotic agent (Stambolsky et al. 2010).”
BackgroundSelf-citationGarritano, S., Gemignani, F., Palmero, E. I., Olivier, M., Martel-Planche, G., Le Calvez-Kelm, F., Brugiéres, L., Vargas, F. R., Brentani, R. R., Ashton-Prolla, P., et al. (2010) · Human Mutation · doi:10.1002/humu.21151 · Cited by 153
Zalcenstein, A., Stambolsky, P., Weisz, L., Müller, M., Wallach, D., Goncharov, T. M., Krammer, P. H., Rotter, V., & Oren, M. (2003) · Oncogene · doi:10.1038/sj.onc.1206724 · Cited by 123 · cited 2×
“Among these apoptotic proteins are Fas/Apo-1 (Gurova et al. 2003; Zalcenstein et al. 2003), caspase 9 (Chee et al.”
BackgroundSelf-citationBuganim, Y., Solomon, H., Rais, Y., Kistner, D., Nachmany, I., Brait, M., Madar, S., Goldstein, I., Kalo, E., Adam, N., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2661 · Cited by 77
Self-citationUbertini, V, Norelli, G., D'Arcangelo, D., Gurtner, A., Cesareo, E., Baldari, S., Gentileschi, M. P., Piaggio, G., Nisticò, P., Soddu, S., et al. (2015) · Oncogene · doi:10.1038/onc.2014.191 · Cited by 75 · cited 3×
“Additional inflammatory mechanisms that mut-p53 isoforms use to promote carcinogenesis are suppression of the secreted IL1 receptor antagonist by binding to its promoter with the corepressor MAFF (Ubertini et al. 2015), induction of NF-kB2 activation via recruitment of CBP and STAT2 to acetylate NF-kB2 promoter (Vaugh…”
BackgroundInfluentialHuang, X., Zhang, Y., Tang, Y., Butler, N., Kim, J., Guessous, F., Schiff, D., Mandell, J., & Abounader, R. (2013) · Neoplasia · doi:10.1593/neo.13376 · Cited by 53 · cited 3×
“…above. mut-p53 shows GOF by up-regulating MDR1 (Dittmer et al. 1993), although these very same efflux pumps are considered to be pivotal means to detect and isolate CSCs. Additionally, mut-p53 confers apoptosis resistance by affecting Bcl-2 family members (Brosh and Rotter 2009; Huang et al. 2013).”
Background
Cited by
Targeting p53 pathways: mechanisms, structures, and advances in therapy
Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016
“Conversely, mutant p53 contributes to the maintenance of cancer stem cells.(157) Mutant p53 enhances the proliferation of cancer stem cells by regulating WASP-interacting proteins.”
BackgroundGain-of-function mutant p53 in cancer progression and therapy
Zhang, C., Liu, J., Xu, D., Zhang, T., Hu, W., & Feng, Z. (2020) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjaa040 · Cited by 334
Attenuating the p53 Pathway in Human Cancers: Many Means to the Same End
Wasylishen, A. R., & Lozano, G. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026211 · Cited by 123
Metadata
- Authors
- Shetzer, Y., Molchadsky, A., & Rotter, V.
- Venue
- Cold Spring Harbor Perspectives in Medicine
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2016-05-27
- Volume
- 6
- Issue
- 10
- Pages
- a026203
- ISSN
- 2157-1422 (ISSN-L)
- OpenAlex
- W2469478085
- Cited by
- 50
- References
- 40
- Type
- posted content
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.